Under the two-year deal AMRI – which has worked with Kopp since 2006 - will provide various discovery-related services that include medicinal chemistry, DMPK and computer-aided drug discovery (CADD).
As part of the scope of work, AMRI scientists will collaborate with Knopp scientists and project leaders on selected novel drug discovery programs. The collaboration is extendable after two years by mutual agreement.
"We are pleased to expand our relationship with Knopp Biosciences, a company that values innovation through collaboration," said AMRI CEO, Thomas E. D'Ambra
He added that: "This agreement will combine AMRI's broad range of drug discovery capabilities, with more than 20 years of CNS experience, to assist Knopp in its goal of delivering safe and effective treatments for unmet medical need."